Indoco Remedies Q4 Results: Loss halves, EBITDA returns to profit; shares rally 13%

Indoco Remedies

reported a sharp improvement in its March quarter earnings on May 7, with losses narrowing significantly and operating performance returning to positive territory, aided by strong growth in its international formulations business.

The pharmaceutical company posted a net loss of ₹22 crore for the fourth quarter, compared with a loss of ₹40 crore in the corresponding period last year. Revenue for the quarter rose 22% year-on-year to ₹476 crore from ₹390 crore earlier.

Operationally, the company reported EBITDA of ₹50.2 crore, a notable turnaround from an EBITDA loss of ₹1 crore in the year-ago quarter. EBITDA margin stood at 10.6%, reflecting improved operating leverage and better business traction across key segments.

Commenting on the performance, Managing Director Aditi Panandikar said revenue growth during the quarter and the full financial year was primarily driven by a healthy performance in the international formulations business, along with steady growth in the API and services segments.

For the full financial year FY26, the company reported revenue of ₹1,633.5 crore, compared with ₹1,494.8 crore in the previous year. EBITDA margin for the year improved to 9.6%, with EBITDA at ₹157.2 crore versus ₹128 crore in the previous financial year.

The board has recommended a dividend of ₹0.20 per equity share of face value ₹2 for FY26, subject to shareholder approval at the company’s upcoming annual general meeting.

Following the earnings announcement, investor sentiment turned sharply positive. Shares of Indoco Remedies surged more than 13% during the session to hit an intraday high on the NSE before trimming some gains.

Indoco Remedies is an India-based pharmaceutical company engaged in the development, manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs). The company has a presence across domestic and international markets, with businesses spanning branded generics, contract manufacturing and pharmaceutical services.